Fig. 4: Chronic low-dose effects of GLP-1RA/tesaglitazar in DIO mice.
From: GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice
a–d, Body weight (a), cumulative food intake (b) and change in fat (c) and lean tissue mass (d) of 36-week-old male C57BL/6J DIO mice treated for 7 days with either vehicle or 5 nmol kg−1 per day of either GLP-1 or GLP-1/tesaglitazar. e–g, Fasting levels of blood glucose (e) and i.p. GTT (f,g). Sample sizes for treatment with Vhcl, GLP-1RA or GLP-1RA/tesaglitazar are n = 5/7/6 (a–g). Cumulative food intake was assessed per cage in n = 3/4/3 cages containing n = 5/7/6 mice (d). Data in a,b and f have been analysed by two-way ANOVA with Bonferroni post hoc comparison for individual time points. Data in c, d, e and g have been analysed by one-way ANOVA using the Bonferroni’s multiple comparison test. Data represent means ± s.e.m.; asterisks indicate *P < 0.05, **P < 0.01, ***P < 0.001. Red asterisks indicate comparison to the GLP-1RA, black asterisks indicate comparison to Vhcl. Exact P values for treatment effects are: a P = 0.044 and P = 0.0007, c all P < 0.0001; d P = 0.0099 and P = 0.0284; e P = 0.0035 and P = 0.0242; f P = 0.0030, P = 0.0004 (red asterisks) and P < 00001 (black asterisks), g P = 0.0027 and P = 0.030. For exact P values at individual time points (a,b,f), see the data source file.
